• Landline:512-347-2000
  • Email:stafford@benchmarkcorporate.com

Clinical Research and Testing Site

  • Posted on
  • 19
Specifications
EBITDA$116,00
Revenue$1,021,000
Client CodeVen415
EBITDA Range under-250K
Revenue Range 1M-5M
Sector Care,-Health-and-Medical
Region Southwest-US,Southwest-US
Deal Structure Full-Sale
HeadquartersSan Antonio, Texas
Description

The Company is an independent clinical research site. It provides exceptional expertise in an array of therapeutic areas of medicine as they relate to the research of drugs, vaccines, and
medical devices.

Key aspects
· Trait-searchable management database of over 22,000 potential subjects
· Experienced Physicians in all aspects of clinical research
· Licensed nurses and respiratory therapist with a minimum of seven years clinical research experience
· Expanded Company budgets for current and upcoming studies that have been negotiated to an average of 22% above initial offers
· Broad range of clinical indications with studies in pulmonary, allergy, internal medicine, vaccines, and devices
· The reason for the decline in 2017 was the discontinuity of the allergic rhinitis research. In 2017, DXRG had multiple major projects get put on “hold”, a usual industry occurrence, according to management

Opportunities
· Hire dedicated business development specialist
· Expand operations to add additional site locations and centralize business development
· Explore additional studies regarding new pharmaceuticals and vaccines that are being developed
· Increase subject base

Headquartered
San Antonio, Texas

Current markets
The Company provides services to pharmaceutical, vaccine, and device companies from the United States, Canada, Europe, India, and Japan.

Real estate
The Company leases one suite in a Class A Medical Office Building in San Antonio, Texas from an unrelated third party. The building is one block from The University of Texas Health Science Center.

Shareholder/owner objectives
Two active owners seek a full sale of the business as they are anticipating retirement. All other partners are inactive; however, the majority shareholder and the other owner believe that selling is an exit strategy for them that will allow them to continue working in full-time roles for additional years. The two physicians who are seeking retirement would like to remain onboard as investigators until retirement.

Year End
08/31/2018
YTD
$’000
08/31/2017
YTD
$’000
08/31/2016
YTD
$’000
08/31/2015
YTD
$’000
08/31/2014
YTD
$’000
Revenue 1,021 1,232 2,218 2,125 2,368
Gross Profit 1,021 1,232 2,218 2,125 2,368
Adj. EBITDA* 116 -73 246 0 183

* Profit before interest, tax, depreciation and amortization (non-cash items)[/cs_table]